Navigation Links
Targeted agent blocked growth of deadly brain cancer in preclinical studies
Date:3/30/2010

Washington, DC A drug already in clinical trials to treat a variety of tumors shows a remarkable ability to shut down growth of glioblastoma in both laboratory cells and in animals, say researchers from Georgetown Lombardi Comprehensive Cancer Center and the University of California, San Francisco (UCSF). In their experiments, the agent put a brake on growth of laboratory cancer cell lines, and no mice with glioblastoma in their brain died as a result of their tumor while on therapy.

They say their findings, reported in the April 15 issue of Cancer Research, provides hope that the drug, PD-0332991, could offer a new treatment option for glioblastoma, which is the most common as well as the deadliest form of brain cancer. A clinical trial testing the therapy in patients with recurrent brain cancer is under development.

"We have had just amazing results in these preclinical studies," says Todd Waldman, MD, PhD, an associate professor of oncology at Lombardi. "We are hopeful it will prove to be effective in brain cancer patients for which there is little effective therapy."

Waldman is the study's co-lead investigator, along with C. David James, PhD, professor of neurological surgery at UCSF. "What is especially encouraging about this agent is that we found it can easily pass through the blood-brain barrier and access glioblastoma, and that there is already a simple test available for screening glioblastoma patients in advance to see whether or not they should be responsive to this therapy," James says.

Given the molecular data from a recently published study by The Cancer Genome Atlas Research Network, about 90 percent of glioblastoma patients have a molecular profile that would make them candidates for the drug, the researchers say.

The drug is currently being tested in clinical trials for otherwise untreatable teratomas, as well as multiple myeloma and breast cancer. It is designed to shut down the activity of molecules, cyclin-dependent kinases 4 and 6 (cdk4/6), that drive cell division. "In normal cells, these kinases are kept under exquisite control by a gene known as p16," says Waldman. "But in glioblastoma, and other cancers, p16 is frequently deleted, and these two kinases are uncontrollably activated, which drives the cell to divide and form cancer."

The agent, however, does not work if the cancer is missing expression of a tumor suppressor protein known as retinoblastoma (Rb) because Rb is needed to control growth in these cells even if cdk4/6 are inhibited. A test to determine if RB is present is already being used to screen patients for use of PD-0332991 in the ongoing clinical trials.

A research team at Georgetown led by Waldman, conducted laboratory studies on 21 different cell lines derived from the tumors of patients with glioblastoma. They tested PD-0332991 at various concentrations to see if it could stop growth of the cancer cells, and found it to be effective in all 16 cell lines with a functioning Rb gene, but it did not work in 5 cell lines missing Rb. "The agent was very potent in stopping cancer growth, but it was also quite clean in that it only seemed to inhibit the two molecules it targeted, and no other," says Waldman. "Most drugs are dirtier than that they hit multiple unintended targets."

What intrigues Waldman, he says, is that no one has discovered what the "normal" function for cdk4/6 is. "Mice lacking either cdk4 or cdk6 grow up to be relatively healthy, so it may be that these kinases are really only important for cancer growth," Waldman says. "That would be an exciting development, if true, but no one knows yet."

James led a team of scientists at UCSF that implanted three different kinds of human glioblastoma directly into the brains of mice, and then they treated them with PD-0332991. They discovered first that the agent effectively reached intracranial tumors "and it wasn't known beforehand that it would, so this was very good news," says James and that the cancer did not grow as long as the mice continued on the drug, but that they quickly died from the cancer when the agent was withdrawn.

Because PD-0332991 itself does not kill cancer cells just arrests their growth the researchers then combined the agent with radiation and found that outcomes were superior to use of PD-0332991 alone. They further successfully tested the agent in mice in which glioblastoma had come back after treatment with temozolomide, a chemotherapy that is the standard-of-care for many patients.

"We don't know how well this agent will perform in patients with glioblastoma, but in the mice we studied, we saw very impressive, durable effect that was sustained as long as therapy was administered," says James.


'/>"/>

Contact: Karen Mallet
km463@georgetown.edu
215-514-9751
Georgetown University Medical Center
Source:Eurekalert

Related medicine news :

1. Survival in metastatic breast cancer patients is improving: targeted therapies have contributed
2. Gene-Targeted Cancer Fix Could Be a Breakthrough
3. Targeted delivery of losartan reduces liver inflammation and scarring
4. Targeted prevention stopped spread of H1N1 at Alabama boys camp
5. Human Touch Introduces New CirQlation™ Elite Foot & Calf Massager Providing Ultimate Targeted Relief for Tired Feet and Calves
6. Middle Schoolers Identify Violent Content in Youth-Targeted Entertainment as a Strong Influence in Causing Youth Violence
7. Targeted therapy prolongs life in patients with HER2-positive breast cancer
8. Targeted Breast Ultrasound Can Reduce Biopsies for Women Under Forty
9. Targeted breast ultrasound can reduce biopsies for women under 40
10. Targeted Testing Receives Favorable Reviews On PADDS, Begins Nationwide Research Study On The Target Tests of Executive Functioning-OV
11. Reportlinker Adds The Future of Senior Nutrition: Key Ingredients, Strategic Issues and Targeted Opportunities for Older Consumers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... ... authorized OSHA Training Institute Education Center headquartered in Northern California, has announced the ... providing occupational safety and health training to public sector employees. , “The primary ...
(Date:12/5/2016)... , ... December 05, 2016 , ... "FCPX Overlay Glare ... but natural lighting effect without heavy rendering or complicated compositing," said Christina Austin - ... media to create an organic spectrum of lights that simulates the look of a ...
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... ... announced it has been featured in SuperbCrew magazine, a leading online tech news ... world. This interview, now featured on SuperbCrew.com, explores the state of enterprise mobility ...
(Date:12/5/2016)... ... December 05, 2016 , ... “Epilepsy Awareness,” ... tomorrow, December 6th, sparks a conversation about epilepsy, bearing down on the social ... people will be diagnosed with epilepsy within their lifetime. With such a large ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... lines. The goal of Castlewood Treatment Centers has always been to promote the ... as many people as possible. In that spirit, Castlewood has announced two new ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , Dec 5, 2016 Research and ... by Product (Instruments, Consumables), Application (Biomedical & Biochemical Research, Disease Diagnostics), ... Global Forecasts to 2021" report to their offering. ... , , ... 730.7 Million in 2021 from USD 574.8 Million in 2016, growing ...
(Date:12/5/2016)... 5, 2016 According to a new market ... Transplantation, Growth Factor Technology, Tissue Scaffolds, Cell-free composites), Application (Hyaline Cartilage, ... market is projected to reach USD 779.8 Million by 2021 from ... during the forecast period of 2016 to 2021. ... ...
(Date:12/5/2016)... India , December 5, 2016 According to a ... Type and by Application - Global Opportunity Analysis and Industry Forecast, 2014 - ... is expected to reach $5,255 million by 2022, growing at a CAGR of ... with more than four-fifths share. Continue Reading ... ...
Breaking Medicine Technology: